Skip to content

Rafael Holdings, Inc. RFL Prepaid Clinical Costs

Prepaid Clinical Costs at other companies

Esperion Therapeutics logo
Esperion TherapeuticsESPR
$5.79M+1,049%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$4.02M-69.8%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$24.82M
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$22.49M+354%
Schering-Plough logo
Schering-PloughSGP
$1.71M+1,187%
Veradermics
 logo
Veradermics MANE
$6.27M+8,039%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept rfl:PrepaidClinicalCosts.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s prepaid clinical costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s prepaid clinical costs?
Rafael Holdings, Inc. (RFL) reported prepaid clinical costs of $2.92M in Q1 2026.
What does prepaid clinical costs mean?
These are payments made in advance to vendors or partners for clinical trial services that have not yet been performed or delivered. This asset represents the company's commitment to future research and development activities. It is a key indicator of the company's near-term pipeline development pipeline and operational cash outflow.